Resala

doi:10.17605/OSF.IO/ZG3US

Title	Authors

Home

Currently, no study has addressed real-life data describing changes in health resource consumption and related costs attributable to mepolizumab treatment. The aim of the current study is to fill this knowledge gap by performing an exhaustive extraction of data for patients receiving mepolizumab in the French single-payer health care system. The change in real-life health-resource usage and costs observed for these patients would provide the first evidence that mepolizumab is changing the care landscape for eligible severe asthma patients.

OSF does not support the use of Internet Explorer. For optimal performance, please switch to another browser.

This website relies on cookies to help provide a better user experience. By clicking Accept or continuing to use the site, you agree. For more information, see our Privacy Policy and information on cookie use.

Start managing your projects on the OSF today.

Free and easy to use, the Open Science Framework supports the entire research lifecycle: planning, execution, reporting, archiving, and discovery.

Create an Account Learn More Hide this message

Main content

Home

Menu

Start managing your projects on the OSF today.

Main content

Links to this project

Home

Menu

Add new wiki page

Page permissions have changed

Wiki page deleted

Connected to the collaborative wiki

Connecting to the collaborative wiki

Collaborative wiki is unavailable

Browser unsupported

Start managing your projects on the OSF today.